P2.07-038 Thyroid Dysfunction Arising During KEYNOTE-001 Associated with Improved Efficacy of Pembrolizumab in NSCLC Patients at UCLA

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of thyroid gland dysfunction in patients with alopecia areate

Introduction: Alopecia areata is a common clinical problem involving 1% of population. It is associated with many autoimmune disorders. One of the most common associations is autoimmune thyroid disease. So it seems necessary to examine the patients with alopecia areata more exactly. The main purpose of this study was to evaluate thyroid gland dysfunction in patients with alopecia areata. Mate...

متن کامل

Is Subclinical Thyroid Dysfunction Associated With with Coronary Heart Disease?

Introduction: Previous cohort studies reported contradictory data on the association between subclinical thyroid dysfunction and coronary heart disease (CHD). Regarding this, the present study was conducted to illuminate this relationship. Materials and Methods: For the purpose of the study, 3,066 participants employed in a study conducted by Azizi et al. aged ≥ 20 years were subjected to thyro...

متن کامل

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

KEYNOTE-030 (ClinicalTrials.gov ID, NCT02083484) was a global expanded access program that allowed access to pembrolizumab, an antiprogrammed death 1 antibody, for patients with advanced melanoma before its regulatory approval. Patients with unresectable stage III/IV melanoma that progressed after standard-of-care therapy, including ipilimumab and, if BRAF mutant, a BRAF inhibitor, were eligibl...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Thoracic Oncology

سال: 2017

ISSN: 1556-0864

DOI: 10.1016/j.jtho.2017.11.097